AstraZeneca Overview
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca Israel was established at the end of 2008 and is based in Kfar Saba, employing over 100 people, specializing in sales, marketing, medical & regulatory affairs. In addition, AstraZeneca Israel has a strong presence of scientific research and development with partnerships across the country. In May 2019 AstraZeneca signed a MOU (memorandum of understanding) with the Israeli innovation authority, committing to invest and support the Israeli healthcare ecosystem. AstraZeneca Israel is proud to be an active part of the AstraZeneca Health Innovation Hubs network alongside the US, China, Sweden, and France
Latest News
growth-positive
3 UK Stocks That May Be Undervalued In October 2025
Nichols plc, a company with a market cap of £396.78 million, supplies soft drinks to various industries globally. The company is trading at a 41.9% discount to its estimated fair value, suggesting it is significantly undervalued. Despite a slight dip in recent earnings, Nichols forecasts robust annual profit growth of 16.4%, surpassing the UK market average. Analysts predict a potential stock price increase of 34.8%. However, the company has an unstable dividend track record, and recent executive changes could affect future performance stability. Overall, Nichols is poised for substantial financial growth, making it an attractive option for investors seeking undervalued stocks.
Management Changes
growth-positive
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study
AstraZeneca announced positive results from the phase III Bax24 study, which evaluated the safety and efficacy of baxdrostat in patients with resistant hypertension. The study showed that baxdrostat significantly reduced systolic blood pressure compared to placebo, with efficacy observed over a 24-hour period. The treatment was well tolerated, with a safety profile similar to previous studies. AstraZeneca plans to share these results with global regulatory authorities. The company has seen a 31.1% increase in shares year-to-date, outperforming the industry average. Baxdrostat is also being investigated for other conditions, including primary aldosteronism and chronic kidney disease.
Product Stage
Sector Update: Health Care Stocks Mixed Thursday Afternoon
The article provides a brief update on the performance of healthcare stocks on a Thursday afternoon, noting that the NYSE Health Care Index was down by 0.1%. However, the article is behind a paywall, and further details are not accessible without a subscription to MT Newswires. The article mentions several stock symbols, including AZN.L, SMMT, XLV, TH.TO, and CMND, but does not provide specific information about any particular company or event. As such, no detailed analysis or classification of impact, issues, or other specifics can be determined from the available text.
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
The article is a brief mention of health care stocks advancing late Tuesday afternoon, with references to the NYSE Health Care Index. It does not provide specific details about any particular company, investment, or event. The text is part of a premium news service, suggesting that more detailed information is available to subscribers. No specific company actions, partnerships, or financial details are discussed in the provided text.
Markets Stay Relatively Calm as Fragile Ceasefire Deal Follows Missile Strikes
The article discusses recent geopolitical tensions between the United States and Iran, following US attacks on Iranian nuclear facilities and Irans retaliatory missile strikes on a US airbase in Qatar. Despite initial fears of escalating conflict, diplomatic efforts led to a ceasefire agreement between Israel and Iran, announced by President Donald Trump. This de-escalation reassured global markets, with oil prices dropping significantly and stock indices like the S&P 500, Nasdaq, and Dow Jones rising. The article also mentions Irans parliamentary vote to potentially close the Strait of Hormuz, a critical oil trade route, though such a move seems unlikely. Overall, the situation appears to be stabilizing, with investors responding positively to the developments.
Team Members
3
Employees: 51-200
Web & Social Links
| Website | www.astrazeneca.com/ |
Locations
Atir Yeda Street 1, Kefar Sava, Israel
Cambridge, UK
Photos & Videos
No files yet
AstraZeneca Business
Business models
—
Product stage
—
Employees
51-200
Sector
—Target Customer
—Core Technology
—Tags (6)
innovation-centerpharmaceuticalsoncologybiopharmaceuticalimmunologyclinical-trialsAstraZeneca Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
AstraZeneca Lifecycle
AstraZeneca News
13 articles
growth-positive
3 UK Stocks That May Be Undervalued In October 2025
Nichols plc, a company with a market cap of £396.78 million, supplies soft drinks to various industries globally. The company is trading at a 41.9% discount to its estimated fair value, suggesting it is significantly undervalued. Despite a slight dip in recent earnings, Nichols forecasts robust annual profit growth of 16.4%, surpassing the UK market average. Analysts predict a potential stock price increase of 34.8%. However, the company has an unstable dividend track record, and recent executive changes could affect future performance stability. Overall, Nichols is poised for substantial financial growth, making it an attractive option for investors seeking undervalued stocks.
Management Changes
growth-positive
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study
AstraZeneca announced positive results from the phase III Bax24 study, which evaluated the safety and efficacy of baxdrostat in patients with resistant hypertension. The study showed that baxdrostat significantly reduced systolic blood pressure compared to placebo, with efficacy observed over a 24-hour period. The treatment was well tolerated, with a safety profile similar to previous studies. AstraZeneca plans to share these results with global regulatory authorities. The company has seen a 31.1% increase in shares year-to-date, outperforming the industry average. Baxdrostat is also being investigated for other conditions, including primary aldosteronism and chronic kidney disease.
Product Stage
Sector Update: Health Care Stocks Mixed Thursday Afternoon
The article provides a brief update on the performance of healthcare stocks on a Thursday afternoon, noting that the NYSE Health Care Index was down by 0.1%. However, the article is behind a paywall, and further details are not accessible without a subscription to MT Newswires. The article mentions several stock symbols, including AZN.L, SMMT, XLV, TH.TO, and CMND, but does not provide specific information about any particular company or event. As such, no detailed analysis or classification of impact, issues, or other specifics can be determined from the available text.
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
The article is a brief mention of health care stocks advancing late Tuesday afternoon, with references to the NYSE Health Care Index. It does not provide specific details about any particular company, investment, or event. The text is part of a premium news service, suggesting that more detailed information is available to subscribers. No specific company actions, partnerships, or financial details are discussed in the provided text.
Markets Stay Relatively Calm as Fragile Ceasefire Deal Follows Missile Strikes
The article discusses recent geopolitical tensions between the United States and Iran, following US attacks on Iranian nuclear facilities and Irans retaliatory missile strikes on a US airbase in Qatar. Despite initial fears of escalating conflict, diplomatic efforts led to a ceasefire agreement between Israel and Iran, announced by President Donald Trump. This de-escalation reassured global markets, with oil prices dropping significantly and stock indices like the S&P 500, Nasdaq, and Dow Jones rising. The article also mentions Irans parliamentary vote to potentially close the Strait of Hormuz, a critical oil trade route, though such a move seems unlikely. Overall, the situation appears to be stabilizing, with investors responding positively to the developments.
growth-positive
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans
AstraZeneca has formed a new collaboration with CSPC Pharmaceutical Group to develop oral medicines using AI technology for immunological diseases and other chronic conditions. The deal involves an upfront payment of $110 million to CSPC and potential additional payments up to $5.2 billion based on development and sales milestones. This partnership builds on AstraZenecas previous investments in China, including a $2.5 billion R&D center in Beijing and collaborations with other Chinese biotechs. The collaboration is part of AstraZenecas strategy to deepen its presence in the Chinese market and leverage AI in drug discovery.
PartnersInvestment
growth-positive
The UK pharmaceutical giant is teaming with Tel Aviv University and the Meuhedet and Leumit health funds on the project.
AstraZeneca has launched the Beam - Illuminating Healthcare Through Data Center in collaboration with Tel Aviv University and the Leumit and Meuhedet health funds. This initiative aims to leverage Israeli digital medical data to enhance understanding of disease mechanisms and improve patient care. The center will utilize anonymized data from health insurance companies, employing AI tools to analyze real-world data. This collaboration between academia, industry, and health services is expected to advance research and medical services, with a focus on data privacy through federated learning. The center represents a significant step forward in data science within the health sector.
Partners
Israeli AI startup forges $18m partnership with AstraZeneca for cancer drug trials
AstraZeneca Shares Drop on Weak Quarterly Report Despite 2024 Growth Guidance
growth-positive
Israel’s Immunai could be the secret weapon to faster drug approvals
American-Israeli company announces latest success story with AstraZeneca.
Immunai, an American-Israeli immunomics company, has announced a successful collaboration with AstraZeneca, utilizing its AI-based Clinical Trial Optimization engine to support the development of AstraZenecas drug, Volrustomig. Immunais technology provided deep immunological insights that were instrumental in advancing the drug through clinical trial phases. This partnership highlights Immunais role in enhancing drug development efficiency and effectiveness. The company leverages its extensive immune database, AMICA, and advanced AI to generate valuable data-driven insights, potentially reducing drug development time and costs. Immunai operates internationally with a team of 160 members and aims to become a market leader in the biopharmaceutical sector.
Partners
growth-positive
AstraZeneca innovation hub seeking Israeli tech as it broadens search for innovation CTech
AstraZenecas BioVentureHub, in partnership with the Swedish government, aims to combine science and tech to support the growth of small organizations. The hub, located in Gothenburg, provides access to AstraZenecas human capital and infrastructure for startups. The initiative also collaborates with The Connector, an innovation program between Sweden and Israel. AstraZeneca has signed an MOU with the Israeli Innovation Authority and has been working with The Connector to support the Israeli healthcare ecosystem. The BioVentureHub has collaborations with various companies, fostering a dare to share culture. AstraZeneca has also established HealthWorks, a hub focused on patient centricity. The company is interested in establishing relationships with Israeli companies and utilizing governmental funding to support them.
PartnersInvestment
growth-positive
https://www.jpost.com/health-and-wellness/pfizer-astrazeneca-help-launch-computational-science-lab-in-israel-682248
Aion Labs, a computational science lab focused on drug discovery, has launched its headquarters in Israel. The lab is a partnership between AstraZeneca, Merck, Pfizer, Teva, Amazon Web Services, and Israel Biotech Fund. Aion aims to create and adopt new AI technologies to transform the drug discovery and development process. The lab will have a wet lab for biomedical experiments and a cloud-based computational lab environment for developing new algorithms. The partners hope to improve predictability, reduce time, and save money in drug development, as well as position Israel as a leader in the pharma R&D industry. AION Lab also plans to support the growth of start-ups in the biotech space. AION has signed with BioMed X and is working with Start-up Nation Central and Science Abroad to attract Israeli life science experts.
PartnersInvestmentExpand
growth-positive
JVP and AstraZeneca Launch Joint Digital-Health Initiative - JVP
Internationally renowned VC JVP and AstraZeneca have launched the call for application for PlayBeyondBio, a program designed to attract, screen, develop, and promote innovative startups in the digital health field. PlayBeyondBio is a strategic partnership between AstraZeneca, JVP, and Israel Initiative, in collaboration with other organizations. The program aims to supercharge digital health startups by providing guidance, mentorship, and access to resources. The selected startups will receive exclusive guidance from AstraZeneca and JVP experts, as well as support from Microsoft for Startups. PlayBeyondBio will focus on various clinical areas and technological solutions. Applications close on March 11th, 2020.
PartnersInvestment
AstraZeneca Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 193 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
AstraZeneca Internal
Recent Updates
Ayelet Levi Shinebox
· yayhosh@gmail.com · Automatic · 2023-03-28 08:03:20.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-22 06:26:11.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-09-23 13:00:30.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-09-23 12:56:26.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 05:07:25.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2022-11-14 09:25:25.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-09-23 12:57:34.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 05:07:25.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-09-23 13:00:30.000000
Ayelet Levi Shinebox
· yayhosh@gmail.com · Manual · 2023-03-28 08:03:20.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-10-08 08:20:47.000000
Yanina Wainscheinker
· yanina.wainscheinker@sncentral.org · Manual · 2023-03-23 13:20:20.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2025-02-06 12:40:57.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-07 13:40:56.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-07 13:05:28.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-04 06:07:18.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-04 06:07:18.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-04 06:07:18.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-04 06:07:18.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-04 06:07:18.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-04 06:07:18.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-04 06:07:18.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-04 06:09:53.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-04 06:09:53.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-04 06:12:06.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-04 06:12:06.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-07 13:33:58.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-07 13:37:28.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-07 13:45:29.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-04-07 13:37:46.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 67/100 |
| Missing | product stage, sector, founding month, business model, video or image, funding rounds, markets, not claimed |
| BI Verification | Maor Perlov |
| Phone | +972732226099 |
| Creator | Maor Perlov |
| Creator email | maorperlov@gmail.com |
| Last updater | Maor Perlov |
| Updater email | maor.perlov@sncentral.org |
| Last update | 2024-09-23T00:00:00.000Z |
| Created | 2022-04-04T00:00:00.000Z |
| Status detail | Public on LSE on Jun, 1993;Public on NYSE on Jun, 1993; |